P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions

Pathology Research and Practice

Volumn 212, Issue 10, 2016, Pages 876-879

  Shooshtarizadeh, Tina ^a,b   Rahimi, Mandana ^b   Movahedinia, Sajjadeh ^b  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Giant cell tumor of bone; Giant cell rich lesions; p63 Expression

Indexed keywords

PROTEIN P63; CKAP4 PROTEIN, HUMAN; MEMBRANE PROTEIN; TUMOR MARKER;

ADOLESCENT; ADULT; AGED; ANEURYSMAL BONE CYST; ARTICLE; BONE TUMOR; CHILD; CHONDROBLASTOMA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; OSTEOCLASTOMA; OSTEOSARCOMA; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BONE CYSTS, ANEURYSMAL; BONE NEOPLASMS; GIANT CELL; GIANT CELL TUMOR OF BONE; METABOLISM; MIDDLE AGED; PATHOLOGY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; BIOMARKERS, TUMOR; BONE CYSTS, ANEURYSMAL; BONE NEOPLASMS; CHILD; CROSS-SECTIONAL STUDIES; DIAGNOSIS, DIFFERENTIAL; FEMALE; GIANT CELL TUMOR OF BONE; GIANT CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MEMBRANE PROTEINS; MIDDLE AGED; OSTEOSARCOMA; YOUNG ADULT;

EID: 84994406821     PISSN: 03440338     EISSN: 16180631     Source Type: Journal    
DOI: 10.1016/j.prp.2016.07.007     Document Type: Article

References (21)

1. [1] Folpe, A.L., Inwards, C.Y., Bone and Soft Tissue Pathology. 2010, Elsevier Health Sciences.
2. [2] Saikia, K.C., et al. Local recurrences after curettage and cementing in long bone giant cell tumor. Indian J. Orthop. 45:2 (2011), 168–173.
3. [3] Miller, I.J., et al. A case of recurrent giant cell tumor of bone with malignant transformation and benign pulmonary metastases. Diagn. Pathol., 5, 2010, 62.
4. [4] Mendenhall, W.M., et al. Giant cell tumor of bone. Am. J. Clin. Oncol. 29:1 (2006), 96–99.
5. [5] Arnold, R.T., et al. Best cases from the AFIP: necrotic giant cell tumor of bone manifesting with pathologic fracture. Radiographics 31:1 (2011), 93–98.
6. [6] Murphey, M.D., et al. From the archives of AFIP. Imaging of giant cell tumor and giant cell reparative granuloma of bone: radiologic-pathologic correlation. Radiographics 21:5 (2001), 1283–1309.
7. [7] Turcotte, R.E., Giant cell tumor of bone. Orthop. Clin. North Am. 37:1 (2006), 35–51.
8. [8] Turcotte, R.E., et al. Giant cell tumor of long bone: a Canadian Sarcoma Group study. Clin. Orthop. Relat. Res. 2002:397 (2016), 248–258.
9. [9] Balke, M., et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J. Cancer Res. Clin. Oncol. 134:9 (2008), 969–978.
10. [10] Brant, W.E., Brant, W.E., Helms, C., Fundamentals of Diagnostic Radiology, vol. 4, 2012, Lippincott Williams & Wilkins.
11. [11] Dickson, B.C., et al. Giant cell tumor of bone express p63. Mod. Pathol. 21:4 (2008), 369–375.
12. [12] de la Roza, G., p63 expression in giant cell-containing lesions of bone and soft tissue. Arch. Pathol. Lab. Med. 135:6 (2011), 776–779.
13. [13] Hammas, N., et al. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience. Diagn. Pathol., 7, 2012, 130.
14. [14] Lau, C.P., et al. p63 Regulates cell proliferation and cell cycle progressionassociated genes in stromal cells of giant cell tumor of the bone. Int. J. Oncol. 42:2 (2013), 437–443.
15. [15] Lee, C.H., et al. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone. Mod. Pathol. 21:5 (2008), 531–539.
16. [16] Maues De Paula, A., et al. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50% of cells is stained. Virchows Arch. 465:4 (2014), 487–494.
17. [17] Yanagisawa, M., et al. p63 as a prognostic marker for giant cell tumor of bone. Ups. J. Med. Sci. 118:1 (2013), 23–28.
18. [18] Kaghad, M., et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:4 (1997), 809–819.
19. [19] Melino, G., p63 Is a suppressor of tumorigenesis and metastasis interacting with mutant p53. Cell Death Differ. 18:9 (2011), 1487–1499.
20. [20] Westfall, M.D., et al. The delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol. 23:7 (2003), 2264–2276.
21. [21] Yang, A., et al. p63, a p53 Homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell 2:3 (1998), 305–316.